• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制

Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology.

作者信息

Liu Yingying, Tan Yingying, Huang Jiaqi, Wu Chao, Fan Xiaotian, Stalin Antony, Lu Shan, Wang Haojia, Zhang Jingyuan, Zhang Fanqin, Wu Zhishan, Li Bing, Huang Zhihong, Chen Meilin, Cheng Guoliang, Mou Yanfang, Wu Jiarui

机构信息

Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.

Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, China.

出版信息

Front Pharmacol. 2023 Jul 26;14:1243304. doi: 10.3389/fphar.2023.1243304. eCollection 2023.

DOI:10.3389/fphar.2023.1243304
PMID:37564177
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10411345/
Abstract

[This corrects the article DOI: 10.3389/fphar.2022.875700.].

摘要

[本文更正了文章的数字对象标识符：10.3389/fphar.2022.875700。]

相似文献

1
Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology.勘误：基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制
Front Pharmacol. 2023 Jul 26;14:1243304. doi: 10.3389/fphar.2023.1243304. eCollection 2023.
2
Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology.基于16S rRNA、宏基因组测序和网络药理学揭示化滞柔肝颗粒通过肠道菌群治疗非酒精性脂肪肝的机制
Front Pharmacol. 2022 Apr 26;13:875700. doi: 10.3389/fphar.2022.875700. eCollection 2022.
3
Efficacy and safety of Huazhi Rougan granule in the treatment of non-alcoholic fatty liver: a systematic review and meta-analysis.化滞柔肝颗粒治疗非酒精性脂肪肝的疗效与安全性：一项系统评价和Meta分析
Ann Palliat Med. 2021 Dec;10(12):12969-12984. doi: 10.21037/apm-20-1613. Epub 2021 Feb 23.
4
Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet.止食导滞汤对高脂饮食诱导的非酒精性脂肪肝病小鼠肠道菌群的影响。
Front Cell Infect Microbiol. 2023 Jan 4;12:1005318. doi: 10.3389/fcimb.2022.1005318. eCollection 2022.
5
[Huazhi Rougan Granules attenuates steatosis in cell model of nonalcoholic fatty liver disease by inducing autophagy].华致柔肝颗粒通过诱导自噬减轻非酒精性脂肪性肝病细胞模型中的脂肪变性
Zhongguo Zhong Yao Za Zhi. 2023 Apr;48(7):1770-1778. doi: 10.19540/j.cnki.cjcmm.20221111.401.
6
[Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].左归降糖清肝方通过改善肠道菌群稳态促进2型糖尿病合并非酒精性脂肪性肝病小鼠肠黏膜屏障的恢复
Zhongguo Zhong Yao Za Zhi. 2023 Jan;48(2):525-533. doi: 10.19540/j.cnki.cjcmm.20220913.703.
7
Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease.整合血清药物化学、16S rRNA测序和代谢组学以揭示茵栀黄颗粒抗非酒精性脂肪性肝病的物质基础和作用机制。
J Ethnopharmacol. 2023 Jun 28;310:116418. doi: 10.1016/j.jep.2023.116418. Epub 2023 Mar 27.
8
Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice.中药方剂化脂柔肝通过增强小鼠粪便胆汁酸排泄减轻非酒精性脂肪性肝炎
Front Pharmacol. 2022 Jun 1;13:833414. doi: 10.3389/fphar.2022.833414. eCollection 2022.
9
[Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD].[非酒精性脂肪性肝病动物模型中不同病变阶段的肠道菌群多态性]
Zhonghua Gan Zang Bing Za Zhi. 2021 Nov 20;29(11):1069-1076. doi: 10.3760/cma.j.cn501113-20200826-00478.
10
Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease.基于网络药理学的研究，探索二陈汤治疗非酒精性脂肪性肝病的作用及机制。
Anat Rec (Hoboken). 2021 Nov;304(11):2605-2619. doi: 10.1002/ar.24770. Epub 2021 Sep 18.